Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.

BACKGROUND Angiotensin II acts at the cellular level through specific angiotensin II subtype I, AT-1 receptors. Losartan is the first of a new class of antihypertensive agents that specifically block angiotensin II at AT-1 receptors. By acting on complementary and different pharmacologic mechanisms, the concomitant use of low doses of hydrochlorothiazide with losartan may offer an additive antihypertensive activity with fewer adverse experiences. METHODS This double-blind study evaluated losartan concomitantly administered with hydrochlorothiazide as initial therapy in 703 patients with essential hypertension. RESULTS The greatest reduction in blood pressure was observed in the 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide group (17.2 mm Hg in sitting systolic blood pressure and 13.2 mm Hg in sitting diastolic blood pressure [P < or = .001]), and the effects of the two components appeared to be additive. Seventy-eight percent of the patients treated with 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide had an excellent or good antihypertensive response (sitting diastolic blood pressure < 90 mm Hg or > or = 90 mm Hg with a reduction of 10 mm Hg or more). Peak (6 hours after dosing) and trough placebo-adjusted ratios for the losartan-hydrochlorothiazide groups ranged from 62% to 85%, indicating that there was a smooth reduction in sitting diastolic blood pressure that was sustained over 24 hours. The most common clinical adverse experiences (> or = 4%) that occurred with an incidence slightly greater than that reported by the placebo-treated patients were headache, asthenia or fatigue, dizziness, sinusitis, and upper respiratory infection. CONCLUSION The concomitant administration of losartan potassium, 50 mg, with 12.5 mg of hydrochlorothiazide once daily produced an additive reduction in trough sitting systolic and diastolic blood pressure and was well tolerated.

[1]  C. Mörlin,et al.  Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. , 1994, Blood pressure.

[2]  J. Ménard Anthology of the renin-angiotensin system: a one hundred reference approach to angiotensin II antagonists. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[3]  J. Ménard Critical assessment of combination therapy development. , 1993, Blood pressure. Supplement.

[4]  M. Weber,et al.  Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. , 1992, American journal of hypertension.

[5]  J. Laragh Historical perspective on renin system blockade in the treatment of hypertension. , 1992, American journal of hypertension.

[6]  P. Timmermans,et al.  Pharmacology of nonpeptide angiotensin II receptor antagonists. , 1992, Annual review of pharmacology and toxicology.

[7]  N. Kaplan The case for low dose diuretic therapy. , 1991, American journal of hypertension.

[8]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[9]  M. Brodie,et al.  Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. , 1990, BMJ.

[10]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. , 1990, American journal of hypertension.

[11]  J. Ménard,et al.  Comparison of Increase in the Enalapril Dose and Addition of Hydrochlorothiazide as Second‐Step Treatment of Hypertensive Patients Not Controlled by Enalapril Alone , 1989, Journal of cardiovascular pharmacology.

[12]  G. McVeigh,et al.  The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. , 1988, BMJ.

[13]  L. Hansson,et al.  Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients. , 1988, American journal of hypertension.

[14]  S. Snapinn,et al.  Evaluating the efficacy of a combination therapy. , 1987, Statistics in medicine.

[15]  K. Catt,et al.  The role of angiotensin II receptors in vascular regulation. , 1984, Journal of cardiovascular pharmacology.

[16]  R. Alexander,et al.  Identification and Characterization of the High Affinity Vascular Angiotensin II Receptor in Rat Mesenteric Artery , 1980, Circulation research.

[17]  P. McCullagh Regression Models for Ordinal Data , 1980 .